Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Medicover - Ex-India: Sales light, margins in line, HS ahead

04 november 2026

<a id="bm-comp-fd6b4a76-7ff1-4513-9dbe-f3759bea6713" name="bm-comp-fd6b4a76-7ff1-4513-9dbe-f3759bea6713" class="BMCustomAnchor"></a><table><tr><td bm-component-id="fd6b4a76-7ff1-4513-9dbe-f3759bea6713" style="vertical-align: top; width:100.000000%;"><ul><li>-4%/-2% adj. EBITDA vs ABGSCe/Infront cons in Q3</li><li>Cons. likely to lower adj. EBITDA &#8216;26e by ~1%</li><li>Trading at 10.9x '26e EV/EBITDA</li></ul></td></tr></table><a id="bm-comp-46dfedaa-94f2-4a6a-9070-61a48e3b6b87" name="bm-comp-46dfedaa-94f2-4a6a-9070-61a48e3b6b87" class="BMCustomAnchor"></a><table><tr><td bm-component-id="46dfedaa-94f2-4a6a-9070-61a48e3b6b87" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Q3 results: Small sales miss, margins in line</h3><p>Medicover reported a third quarter with a miss on sales but margins in in line, now on a continuing operations basis ex India. Q3 sales were EUR 571m (-4% vs ABGSCe, -2% vs cons). Total organic sales growth in the quarter was +8.0% (ABGSCe +12.4%). Adj. EBITDA was 101m (-4% vs ABGSCe, -2% vs cons), for a margin of 17.8% (ABGSCe 17.8%, cons 17.8%), up ~20bps y-o-y on the restated base. Total NRI in Q3 was EUR -2m (ABGSCe EUR -4m, cons EUR -3m). EBIT of 49.3m was 1% above ABGSCe and 3% above cons, while net profit of 25m was 8% below ABGSCe and 2% above cons, as FX losses on euro leases weighed on the financial result. Healthcare Services had a strong quarter, with organic growth of 8.0% and the EBITDA margin up to 19.8% from 19.1% restated. EBITDAaL margin of 14.5% was above ABGSCe (13.3%). Stronger Polish sports/wellness and ambulatory clinics were offset by weaker hospitals in Poland and Romania and German dental. Diagnostic Services was softer, with organic growth of 8.5% (13% ABGSCe) and the EBITDA margin declining to 18.5% from 18.7%. FFS growth of ~10% across key markets (strongest in SEE) and a favourable shift toward advanced tests were offset by weak Germany and genetics. Overall, a mixed report with a top-line miss but better Healthcare margins.</p><h3 class="bm-h3" style="text-align:left;">Outlook: Targets unchanged until India closes</h3><p style="text-align:left;">Management reiterated the 2026-2028 targets (organic revenue &gt;EUR 3.25bn, adj. organic EBITDA &gt;EUR 600m, leverage &#8804;3.0x) and says it is &#8220;in line with plan&#8221; nine months in. The targets remain unchanged until the India divestment closes and still reflect group total including India, so we expect them to be restated on a continuing-operations basis afterwards. Leverage was 2.7x vs 3.1x at FY25, inside targets, helped by the India reclassification. Medicover flags softer public reimbursement and the German genetics reimbursement reform (effective October) as near-term pressure, with constrained public access supporting private-pay demand over the medium term. The India sale (~EUR 0.74bn gross) is expected to close by end-November. Otherwise, the outlook commentary is strategic, with no new formal guidance.</p><h3 class="bm-h3">Conclusion: trading at 10.9x EV/EBITDA '26e</h3><p>Based on the Q3 deviation, we believe cons. might lower adj. EBITDA &#8216;26e by ~1%. The stock has been up ~23% L3M and is trading at 10.9x-9.1x EV/EBITDA for '26e-'27e. Conference call at 09.30 CET today. Link for audiocast <a data-bm-trackable="false" href="https://medicover.events.inderes.com/q3-report-2026/register" target="_blank">here</a>.</p><br /><table id="bm-img-e01118e3-6bb3-4155-8027-cb0e3cd2c0ab" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Deviation table</td></tr><tr><td><img bm-img-encrypt="e01118e3-6bb3-4155-8027-cb0e3cd2c0ab" bm-img-original-height="733" bm-img-original-width="909" bm-img-svg="image:image_upload/100254_4d9c07d1-89e7-4d0e-822d-1702fd9eb982.svg" bm-img-width-hint="100%" id="bm-id-e01118e3-6bb3-4155-8027-cb0e3cd2c0ab" src="https://abgsc.bluematrix.com/images/image_upload/100254_4d9c07d1-89e7-4d0e-822d-1702fd9eb982_732.png" svg="/nas/web/clients/abgsc/images/image_upload/100254_4d9c07d1-89e7-4d0e-822d-1702fd9eb982.svg" width="726" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, Company data, Infront consensus</td></tr><tr><td class="xslt-img-footnote">Q3'25 are not restated numbers</td></tr></table></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-11-19 Tempest Security - Growth returns but margins lag Tempest Sec.. Analys
2026-11-19 Coor - Restarts the M&A engine Coor Analys
2026-11-18 Eltel - CMD: Growth follows the margin repair Eltel Analys
2026-11-16 Petrolia Noco - Q3 impacted by underlift Petrolia Noco Analys
2026-11-16 Proact - CMD takeaways: Clear path to 2030 targets Proact Analys
2026-11-16 Donkey Republic - Wins 1,700-bike Karlsruhe contract Donkey Repu.. Analys
2026-11-16 Ogunsen - Back to growth with a leaner base Ogunsen Analys
2026-11-15 Isofol Medical - Clinical momentum builds ahead o... Isofol Medical Analys
2026-11-13 Clavister - Scaling up with civilian business nex... Clavister Analys
2026-11-12 Generic - Seasonality in volumes with margins hol... Generic Analys
2026-11-12 Xplora Technologies - Strong beat, but shouldn't ... Xplora Tech.. Analys
2026-11-12 Clavister - Scalability on full display Clavister Analys
2026-11-12 Generic - Softer growth but stronger earnings Generic Analys
2026-11-11 Ferronordic - The new normal Ferronordic Analys
2026-11-11 Proact - New targets include adj. EPS doubling 20... Proact Analys
2026-11-11 Ferronordic - Positive trend continues Ferronordic Analys
2026-11-10 Proact - Ahead of CMD Proact Analys
2026-11-10 G5 Entertainment - Estimates raised on lower costs G5 Entertai.. Analys
2026-11-10 Coor - Momentum building in Norway Coor Analys
2026-11-09 Generic - A broader base to grow from Generic Analys